The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Issue 10 (14th October 2021) - Masanas, Marc; Masiá, Nuria; Suárez‐Cabrera, Leticia; Olivan, Mireia; Soriano, Aroa; Majem, Blanca; Devis‐Jauregui, Laura; Burgos‐Panadero, Rebeca; Jiménez, Carlos; Rodriguez‐Sodupe, Pau; Boloix, Ariadna; Toledano, Ignasi; et al.